17 January 2023: Original Paper
Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients
Panarat Noiperm ABCDEF , Jakrawadee Julamanee ABCDEFG* , Pongtep Viboonjuntra ADE , Arnuparp Lekhakula ABCDEDOI: 10.12659/AOT.938595
Ann Transplant 2023; 28:e938595
Table 2 Transplant parameters and peri-transplant outcomes.
| Myeloma (n=40) | Lymphoma (n=18) | |
|---|---|---|
| Median days of stem cell harvest (range) | 1 (1–3) | 2 (1–5) |
| Median days from apheresis to reinfusion (range) | 2 (2–4) | 8 (3–11) |
| CD34 cell dose (million/kg) | 7.59 (4.6–34) | 6.9 (4–25) |
| CD34 cell viability before infusion (%) | 99.1 (97.5–99.8) | 97.1 (94–98.2) |
| Median time to neutrophil engraftment, days (range) | 9 (7–19) | 13 (8–53) |
| Median time to platelet engraftment, days (range) | 11 (7–18) | 14 (8–61) |
| Incidence of graft failure | 0 | 2 (11.1) |
| Number of packed cell units transfused (range) | 2 (0–8) | 5 (1–37) |
| Number of platelet transfusion episodes (range) | 3 (0–20) | 7.5 (1–37) |
| Extra-hematopoietic toxicities | ||
| Oral mucositis | 26 (65) | 15 (83.3) |
| Grade 1–2 | 21 (52.5) | 10 (55.5) |
| Grade 3–4 | 5 (12.5) | 5 (27.8) |
| Febrile neutropenia | 38 (95) | 17 (94.4) |
| Grade 1–2 | 38 (95) | 14 (77.8) |
| Grade 3–4 | 3 (16.7) | |
| Nausea/vomiting (all grades) | 40 (100) | 18 (100) |
| Diarrhea (all grades) | 30 (75) | 10 (55.6) |
| Pulmonary dysfunction (all grades) | 1 (2.5) | 3 (16.7) |
| Neurological dysfunction (all grades) | 2 (11.1) | |
| Engraftment syndrome | 1 (10) | 1 (5.6) |
| Veno-occlusive disease | 1 (5.6) | |
| Documented biological infection | ||
| No organism identified | 29 (72.5) | 11 (61.1) |
| Bacterial | 9 (22.5) | 7 (38.9) |
| Viral | 2 (5) | |
| Septic shock | 1 (2.5) | 4 (22.2) |
| ICU admission | 1 (2.5) | 4 (22.2) |
| Need mechanical ventilator | 1 (2.5) | 3 (16.7) |
| Transplantation outcomes | ||
| Disease response after transplantation | ||
| CR | 34 (85.0) | 14 (77.8) |
| VGPR | 5 (12.5) | |
| PR | 1 (5.6) | |
| PD | 1 (5.6) | |
| Indeterminate | 1 (2.5) | 2 (11.1) |
| Cumulative incidence of relapse (%) | ||
| 5-year | 34.4 | 19.1 |
| 10-year | 47.9 | 28.0 |
| Cumulative incidence of mortality (%) | ||
| 1-year | 4.5 | 24.3 |
| 4-year | 5.9 | 30.9 |
| Status at last follow-up | ||
| Alive with remission | 27 (67.5) | 10 (55.6) |
| Alive with on treatment | 2 (5) | |
| Lost to follow-up | 3 (7.5) | 1 (5.6) |
| Death | 8 (20) | 7 (38.6) |
| Cause of death | ||
| Cancer-related | 4 (50) | 1 (14.3) |
| Complication from therapy | 2 (28.6) | |
| Others | 4 (50) | 4 (57.1) |
| Data are presented as (%) unless otherwise indicated. CD – cluster of differentiation; ICU – Intensive Care Unit; CR – complete response; VGPR – very good partial response; PR – partial response; PD – progressive disease. | ||